Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

DARA Bio - Waiting For Progress

On May 12, 2014, DARA BioSciences, Inc. (DARA) reported financial results for the first quarter ended March 31, 2014. Total revenues in the quarter were $0.161 million, falling short of our $0.220 million estimate and down sequentially from the $0.182 million reported in the fourth quarter 2013. We are very disappointed in the revenue number. DARA has spent significant time and money revamping its commercial efforts. Recent initiatives include:

    Contracting with Alamo Pharma Services, Inc., for a 20 person dedicated sales force to promote Soltamox, Gelclair, and Bionect in October 2013. The deal even allowed for the promotion of three new products - Binosto, Ferralet-90, and Aquoral - owned by Mission Pharmacal, the parent of Alamo Pharma. The...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details